Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Current Deferred Revenue (2024)

Evommune (EVMN) has disclosed Current Deferred Revenue for 1 consecutive years, with $3.0 million as the latest value for Q4 2024.

  • Quarterly Current Deferred Revenue changed N/A to $3.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2024, changed N/A year-over-year, with the annual reading at $3.0 million for FY2024, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2024 was $3.0 million at Evommune.
  • The five-year high for Current Deferred Revenue was $3.0 million in Q4 2024, with the low at $3.0 million in Q4 2024.